NCT01783561View on ClinicalTrials.gov

Early Versus Routine Caffeine Administration in Extremely Preterm Neonates

PHASE4CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Caffeine
Interventions
DRUG

Caffeine

Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 10 minutes within the first 2 hours of life. They will receive a blinded dose of the opposite of what they received in the DR (placebo or caffeine) at 6 hours of life. Therefore, the intervention is timing of initial caffeine dose.

Trial Locations (1)

92103

Sharp Memorial Hospital, San Diego

All Listed Sponsors
lead

Sharp HealthCare

OTHER

NCT01783561 - Early Versus Routine Caffeine Administration in Extremely Preterm Neonates | Biotech Hunter | Biotech Hunter